Evaluation of PD-1 T lymphocytes in bronchoalveolar lavage in lung cancer compared to benign lung diseases.
Bronchoalveolar lavage
Lung cancer
PD-1/PD-L1 pathway
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
03 Aug 2023
03 Aug 2023
Historique:
received:
10
02
2023
accepted:
16
07
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
aheadofprint
Résumé
The expression of the programmed cell death protein 1 (PD-1) has been shown to be markedly increased in tumor-infiltrating lymphocytes. However, the proportion of PD-1 + T cells in the bronchoalveolar lavage (BAL) of lung cancer patients has not been sufficiently evaluated so far. In this prospective study, the proportion of PD-1 + CD4 + as well as PD-1 + CD8 + T cells in BAL samples, isolated from patients with lung cancer, asthma or interstitial lung disease (ILD), were determined via flow cytometry and compared for differences. Bronchoalveolar lavage was performed in 34 patients (14 patients with lung cancer, 10 patients with asthma, 10 patients with ILD). The highest median proportion of PD-1 + CD4 + or PD-1 + CD8 + T cells were found in patients with ILD (83.1% [IQR 72.1; 87.5] and 73.8% [IQR 60.3; 86.3]) followed by patients with lung cancer (66.4% [IQR 59; 69] and 77.1% [IQR 35.8; 82.3]) and patients with asthma (61.3% [IQR 57.4; 70.5] and 57.3% [IQR 46; 65]). Thereby, the difference in the proportion of PD-1 + CD3 + CD4 + BAL cells between ILD patients and asthmatics was significantly different (p = 0.04). The proportion of PD-1 + CD4 + and PD-1 + CD8 + T cells in the BAL of patients with lung cancer did not differ significantly to patients with benign lung diseases. The highest proportion was observed in ILD patients suggesting further research to evaluate the role of the PD-1/PD-L1 pathway in ILD patients.
Identifiants
pubmed: 37535195
doi: 10.1007/s10238-023-01146-6
pii: 10.1007/s10238-023-01146-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–44.
doi: 10.1182/blood-2008-12-195792
pubmed: 19423728
pmcid: 2927090
Nam S, Lee A, Lim J, Lim JS. Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor Cells (MDSCs). Biomol Ther (Seoul). 2019;27(1):63–70.
doi: 10.4062/biomolther.2018.201
pubmed: 30521746
Remon J, Passiglia F, Ahn MJ et al. Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol 2020. Epub ahead of print.
Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small cell lung cancer With PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37:537–46.
doi: 10.1200/JCO.18.00149
pubmed: 30620668
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.
doi: 10.1016/S0140-6736(16)00587-0
pubmed: 26970723
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.
doi: 10.1056/NEJMoa1801005
pubmed: 29658856
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
doi: 10.1056/NEJMoa1504627
pubmed: 26028407
pmcid: 4681400
Domagala-Kulawik J, Guzman J, Costabel U. Immune cells in bronchoalveolar lavage in peripheral lung cancer–analysis of 140 cases. Respiration. 2003;70:43–8.
doi: 10.1159/000068414
pubmed: 12584390
Domagala-Kulawik J, Hoser G, Droszcz P, Kawiak J, Droszcz W, Chazan R. T-cell subtypes in bronchoalveolar lavage fluid and in peripheral blood from patients with primary lung cancer. Diagn Cytopathol. 2001;25:208–13.
doi: 10.1002/dc.2040
pubmed: 11599102
Kwiecien I, Skirecki T, Polubiec-Kownacka M, Raniszewska A, Domagala-Kulawik J. Immunphenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response. Cancers (Basel) 2019;Pii:E567.
Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346–58.
doi: 10.1038/s41590-020-0769-3
pubmed: 32868929
d’Alessandro M, Bergantini L, Mezzasalma F, et al. Immune-Checkpoint expression on CD4, CD8 and NK Cells in blood, bronchoalveolar lavage and lymph nodes of sarcoidosis. Mol Diagn Ther. 2022;26(4):437–49.
doi: 10.1007/s40291-022-00596-0
pubmed: 35761164
pmcid: 9276617
Kronborg-White S, Madsen LB, Bendstrup E, Poletti V. PD-L1 Expression in patients with idiopathic pulmonary fibrosis. J Clin Med. 2021;10(23):5562.
doi: 10.3390/jcm10235562
pubmed: 34884264
pmcid: 8658518
Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.
doi: 10.1186/s13045-022-01242-2
pubmed: 35279217
pmcid: 8917703
Haragan A, Field JK, Davies MPA, Escriu C, Gruver A, Gosney JR. Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response. Lung Cancer. 2019;134:79–84.
doi: 10.1016/j.lungcan.2019.06.005
pubmed: 31320000
Gompelmann D, Sinn K, Brugger J, et al. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. J Cancer Res Clin Oncol. 2022; Online ahead of print.
Wang B, Bai W, Ma H, Li F. Regulatory effect of PD1/PD-ligand 1 (PD-L1) on treg cells in patients with idiopathic pulmonary fibrosis. Med Sci Monit. 2021;27: e927577.
pubmed: 33386384
pmcid: 7786833
Celada LJ, Kropski JA, Herazo-Maya JD, et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci Transl Med. 2018;10(460):eaar8356.
doi: 10.1126/scitranslmed.aar8356
pubmed: 30257954
pmcid: 6263177
Jovanovic D, Roksandic Milenkovic M, Kotur Stevuljevic J, et al. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. J Thorac Dis. 2018;10(12):6660–9.
doi: 10.21037/jtd.2018.11.16
pubmed: 30746211
pmcid: 6344764
Guo X, Qian G. PD-L1 as a novel mediator of lung fibroblast to myofibroblast transition. J Cell Immunol. 2022;4(4):141–4.
pubmed: 36437908
pmcid: 9696593
Galván Morales MA, Montero-Vargas JM, Vizuet-de-Rueda JC, Teran LM. New insights into the Role of PD-1 and Its ligands in allergic disease. Int J Mol Sci. 2021;22(21):11898.
doi: 10.3390/ijms222111898
pubmed: 34769327
pmcid: 8584538
Helou DG, Shafiei-Jahani P, Lo R, et al. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. Nat Commun. 2020;11(1):3998.
doi: 10.1038/s41467-020-17813-1
pubmed: 32778730
pmcid: 7417739
Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D. Common pathogenic mechanisms between idiopathic pulmonary fibrosis and lung cancer. Chest. 2019;156(2):383–91.
doi: 10.1016/j.chest.2019.04.114
pubmed: 31125557